Claims for Patent: 12,290,503

Summary for Patent: 12,290,503

Title:	Compositions and methods for treating epilepsy, seizures and other conditions
Abstract:	Compositions are provided for the liquid oral administration of topiramate and its salts. The invention further provides methods for treating diseases and disorders using the compositions.
Inventor(s):	Yu-Hsing Tu, Ashok Perumal, Kalyan Kathala, Romona BHATTACHARYA
Assignee:	Tulex Pharmaceuticals Inc
Application Number:	US18/409,952
Patent Claims:	1. A method for treating a disease or disorder, or a symptom thereof, comprising orally administering a pharmaceutical composition directly without dilution to a patient in need thereof, wherein the pharmaceutical composition comprises: (a) topiramate, or a pharmaceutically acceptable addition salt thereof, in an amount of about 25 mg/ml; (b) polyethylene glycol in an amount of about 40% w/v to about 60% w/v; (c) glycerin in an amount of about 40% w/v to about 70% w/v; (d) one or more preservatives; and (e) optionally, one or more sweeteners, a flavor component comprising one or more flavor compounds, or a combination thereof; wherein the pharmaceutical composition is administered to the patient at 25 mg/ml of topiramate, or a pharmaceutically acceptable addition salt thereof, and wherein the disease or disorder, or symptom thereof, is selected from: epilepsy, partial-onset seizures, primary generalized tonic-clonic seizures, seizures associated with Lennox-Gastaut syndrome, and migraine. 2. The method of claim 1, wherein the disease or disorder, or symptom thereof, is partial-onset seizures. 3. The method of claim 1, wherein the disease or disorder, or symptom thereof, is a primary generalized tonic-clonic seizure. 4. The method of claim 1, wherein the disease or disorder, or symptom thereof, is a seizure associated with Lennox-Gastaut syndrome. 5. The method of claim 1, wherein the disease or disorder, or symptom thereof, is a migraine. 6. The method of claim 1, wherein the composition is administered to the patient from a direct dosing device. 7. The method of claim 6, wherein the direct dosing device is a measuring device with graduations. 8. The method of claim 6, wherein the direct dosing device contains from 25 mg to 400 mg of topiramate or a pharmaceutically acceptable addition salt thereof. 9. The method of claim 1, wherein the topiramate is in the form of a free acid. 10. The method of claim 1, wherein the polyethylene glycol and the glycerin are present in a combined amount of from about 80% to about 120% w/v in the pharmaceutical composition. 11. The method of claim 1, wherein the polyethylene glycol is present in an amount of about of about 45% w/v to about 55% w/v. 12. The method of claim 1, wherein the glycerin is present in an amount of about 60% w/v to about 70% w/v. 13. The method of claim 12, wherein the glycerin is present in an amount of about 60% w/v to about 65% w/v. 14. The method of claim 1, wherein the one or more sweeteners are present in the pharmaceutical composition in an amount of about 0.5% w/v to about 2% w/v. 15. The method of claim 1, wherein the one or more preservatives comprises parabens, benzyl alcohol, benzoic acid, sorbic acid, sodium benzoate, ascorbic acid, or a salt thereof. 16. The method of claim 1, wherein the one or more preservatives comprises one or more parabens. 17. The method of claim 1, wherein the one or more preservatives is present in an amount of about 0.01% w/v to about 3% w/v. 18. The method of claim 1, wherein the one or more sweeteners are selected from sucralose, aspartame, mannitol, sorbitol, xylitol, acesulfame, neotame, stevia, dextrose, saccharin sodium, fructose, high fructose corn syrup, maltodextrin, and sucrose. 19. The method of claim 1, wherein the pharmaceutical composition has one or more of the following features: (i) a refractive index of from about 1.3 to about 1.38; (ii) a viscosity of 300-600 cps; or (iii) a density of 1.1-1.3.